Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on
therapy on maximal medical treatment versus maximal medical treatment alone in treating
moderate-to-severe ARDS due to SARS-CoV-2.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborators:
IRCCS Azienda Ospedaliero-Universitaria di Bologna University of Milan